{
  "ticker": "CRL",
  "content": "**Report Generated:** January 24, 2026  \n**Next Refresh:** April 25, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# Charles River Laboratories International (CRL) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nCharles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). Charles River provides products and services to help expedite the discovery, early-stage development and safe manufacture of novel drugs and therapeutics. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.\n\n## 2. Current Market Data\n\nThe Charles River Laboratories stock price today is 202.92. The current market capitalization of CRL is $11B. The Charles River Laboratories International Inc share price today is $222.81, reflecting a -0.30% change over the last 24 hours and 1.01% over the past week. The Charles River Laboratories 52-week high stock price is 228.88, which is 2.4% above the current share price. The Charles River Laboratories 52-week low stock price is 91.86, which is 58.9% below the current share price.\n\n## 3. Existing Products/Services\n\nCharles River operates through three core business segments:\n\n### Research Models and Services (RMS)\n- Support your basic research with help from the leading global supplier of laboratory animal models and services. Genetically Engineered Animal Models and Services (GEMS) team helps you select, customize, and maintain the right mice for your research. Services for genetically engineered animals include mouse and rat model creation, breeding, genotyping, and mouse embryo and sperm cryopreservation.\n\n### Discovery and Safety Assessment (DSA)\n- One Step by Charles River is a comprehensive, tailored suite of CRO drug discovery and development services in target discovery, lead optimization, development chemistry, GMP, drug product development and CMC strategy. Charles River can conduct an investigational new drug (IND) study from start to finish, and offers stand-alone studies needed for IND-enabling submissions.\n\n### Manufacturing Solutions\n- Navigate seamlessly throughout the biologic development cycle, from early concept to market-ready with our tailored, CGMP global testing and manufacturing solutions. Our rapid, accurate, and compliant microbial testing solutions optimize your QC workflow.\n- Fastrack your cell and gene development and manufacturing with our end-to-end scalable solutions from early stage-research and testing through commercial release.\n\n## 4. Planned Products/Services/Projects\n\n### Recent Acquisitions (January 2026)\n- Charles River Laboratories has signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a Cambodia-based provider of non-human primates (NHPs) for regulatory required biomedical, pharmaceutical, and toxicological research purposes. The planned K.F. acquisition will further strengthen and secure the supply chain for the Company's Discovery and Safety Assessment (DSA) segment, and will also generate meaningful operating margin improvement through significant cost savings on NHP supply. The transaction is expected to be accretive to non-GAAP earnings per share by approximately $0.25 in 2026 and by approximately $0.60 in 2027.\n\n- Charles River Laboratories has exercised its option to acquire the remaining 79% equity stake that it does not already own of PathoQuest SAS, a Paris, France-based provider of industry-leading next generation sequencing (NGS) solutions for manufacturing quality-control testing for biopharmaceutical companies. PathoQuest is expected to generate annual revenue of approximately $15 to $20 million in 2026.\n\n### Leadership Addition\n- Charles River Laboratories has named Dr. Namandjé N. Bumpus as Senior Vice President, Chief Scientific and Innovation Officer. In this role, Dr. Bumpus will lead the Company's scientific strategy, oversee research and development initiatives, and advance innovation to support clients in accelerating the drug development process.\n\n## 5. Growth Strategy\n\n### Strategic Review and Cost Optimization\n- Charles River has taken extensive action during the current demand environment with a goal to protect its operating margin and reinvigorate earnings growth, and has implemented restructuring initiatives over past several years that are expected to result in approximately $225 million in cumulative, annualized cost savings in 2026. The additional initiatives are expected to generate incremental net cost savings of approximately $70 million annually, which will be fully realized in 2026.\n\n### Capital Deployment\n- Charles River remains committed to deploying capital in a disciplined and value-enhancing manner. As part of this strategy, in October, the Board of Directors approved a new, $1.0 billion stock repurchase authorization.\n\n### 2026 Outlook\n- With regard to its preliminary outlook for 2026, the Company expects the top end of the guidance ranges for 2026 organic revenue growth will be at least flat for both its consolidated outlook and for the DSA segment. \"We believe we are well positioned as we move into 2026 with a clear strategic direction, actions underway to unlock shareholder value, and are cautiously optimistic that the positive signs in the biopharmaceutical demand environment will continue this year.\n\n## 6. Current and Potential Major Clients\n\n- It services nearly all top and mid-tier biopharma players.\n- Charles River Laboratories International serves pharmaceutical and biotechnology companies, hospitals, and academic institutions worldwide.\n- The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development.\n\n## 7. Financial Data & Performance\n\n### 2025 Financial Results\n- **Q1 2025**: First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34\n- **Q2 2025**: Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $3.12\n- **Q3 2025**: For the quarter, revenue was $1.00 billion, a decrease of 0.5% from $1.01 billion in the third quarter of 2024. Third-quarter diluted earnings per share on a non-GAAP basis were $2.43, a decrease of 6.2% from $2.59 per share for the third quarter of 2024.\n\n### Annual Performance\n- Charles River Laboratories revenue for the twelve months ending September 30, 2025 was $4.024B, a 0.92% decline year-over-year.\n- In 2024, CRL's revenue was $4.05 billion, a decrease of -1.92% compared to the previous year's $4.13 billion. Earnings were $10.30 million, a decrease of -97.83%.\n\n## 8. Headwinds & Tailwinds\n\n### Tailwinds\n- We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth. Our clients understand that what truly differentiates Charles River from the competition is the strength and value proposition of our broad, scientifically distinguished portfolio and leading, non-clinical market position.\n- DSA demand trends continued to improve throughout the second half of 2025, resulting in a preliminary estimate for the DSA net book-to-bill of approximately 1.1x in the fourth quarter of 2025. The sequential improvement from the third-quarter level was primarily driven by small and mid-sized biotechnology clients, while net bookings from global biopharmaceutical clients also increased.\n\n### Headwinds\n- This has resulted in a projected revenue decline for Charles River in 2025, mirroring 2024 trends, with expectations of stable but not growing spending from larger pharmaceutical firms and only marginal improvement from biotech clients.\n- Ongoing U.S. government investigations into its non-human primate (NHP) supply chain have also increased legal expenses and accelerated amortization of certain client relationships, impacting profitability in Q1 2025.\n\n## 9. Market Shares\n\nCharles River Laboratories ranks 8th among its top 10 competitors, with the average revenue for this group standing at $6.7 billion. North America held a significant 44% share of the global Contract Research Organization (CRO) market in 2024, a region where Charles River Laboratories maintains a strong presence. The company has a leading position in preclinical services and animal research models, though specific market share percentages for individual segments were not disclosed in the sources.\n\n## 10. Comparison to Competitors\n\n### Main Competitors\nThe primary competitors vying for market share with Charles River Laboratories include major players like IQVIA, LabCorp, ICON, Eurofins Scientific, Fortrea US, SNBL, Envigo, WuXi AppTec, Syneos Health, and PPD. Charles River Laboratories International's main competitors include SNBL, Eurofins, ICON, Fortrea US, Envigo and IQVIA.\n\n### Competitive Position\n- Charles River's reputation for quality and scientific expertise supports its leading position in the research model and preclinical trial markets.\n- Compared to Charles River Laboratories' competitors on Comparably, Charles River Laboratories ranks 1st in CEO Score. 20 Customers rate Charles River Laboratories' Product Quality Score a 3.7/5, which ranks it 1st against its competitors. 30 Customers rate Charles River Laboratories' Net Promoter Score a 3, which ranks it 1st against its competitors.\n\n## 11. Partnerships, Mergers and Acquisitions\n\n### Historical Acquisitions\nCharles River Laboratories has completed 30 acquisitions so far, with an average acquisition amount of $217M. Charles River Laboratories has made a total of 30 acquisitions. Key recent acquisitions include:\n- In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business. In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million. In March 2021, Charles River announced the acquisition of Retrogenix for $48 million. In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.\n\n### Strategic Partnerships\n- Charles River Laboratories announced a collaboration with The Francis Crick Institute to accelerate Antibody-Drug Conjugate (ADC) drug discovery and development. The partnership leverages phage display libraries and advanced in vitro profiling to provide a seamless, end-to-end solution for pharma clients. The company formed a strategic partnership with X-Chem, Inc., granting clients access to X-Chem's DEL platform featuring over 15 billion compounds. This move is expected to enhance hit identification and streamline the early stages of therapeutic discovery.\n\n## 12. Recent Developments\n\n### Strategic Review Update (November 2025)\nCharles River Laboratories International, Inc. (NYSE: CRL) today announced an update on its Board of Directors' comprehensive strategic review of the Company's business and growth prospects. The Board strongly supports the Company's strategic direction and believes it should continue to focus on strengthening its leading scientific portfolio within its core markets, divesting underperforming or non-core assets, maximizing its financial performance, and maintaining a disciplined approach to capital deployment.\n\n### Demand Recovery Signals\nThe company reported that demand in its Discovery and Safety Assessment (DSA) segment strengthened through the second half of 2025, with a preliminary DSA net book-to-bill of approximately 1.1x in the fourth quarter, meaning new DSA bookings exceeded revenue.\n\n### Analyst Activity (January 2026)\n- Mizuho set a $215.00 price objective on Charles River Laboratories International in a report on Friday, January 9th. Bank of America upgraded Charles River Laboratories International from a \"neutral\" rating to a \"buy\" rating and set a $225.00 target price for the company in a research report on Monday, December 15th.\n- Charles River price target raised to $231 from $224 at Baird January 13, 2026 TipRanks · Charles River price target raised to $260 from $250 at Evercore ISI January 13, 2026 TipRanks\n\n## 13. AI Investment Rating & Fair Value Assessment\n\n### Analyst Consensus\n- Charles River Laboratories Intl has a consensus rating of Moderate Buy which is based on 8 buy ratings, 4 hold ratings and 0 sell ratings. The average price target for Charles River Laboratories Intl is 212.80.\n- One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock.\n\n### Investment Strengths\n- Leading position in CRO market with differentiated scientific portfolio\n- Strong relationships with top biopharma clients\n- Improving demand trends in DSA segment with book-to-bill above 1.0x\n- Significant cost savings initiatives ($295M+ in 2026)\n- Strategic acquisitions enhancing supply chain security and capabilities\n- Strong balance sheet with disciplined capital allocation\n\n### Investment Risks\n- Regulatory risks from animal testing phase-outs\n- Dependence on biotech funding cycles\n- NHP supply chain investigations\n- Revenue headwinds from pricing pressure\n- Execution risk from ongoing strategic review\n\n### Buy Rating: 7.2/10\n\nGiven Charles River's strong market position, improving demand trends, significant cost optimization efforts, and strategic acquisitions, the company demonstrates solid fundamentals despite near-term challenges. The improving book-to-bill ratio and analyst upgrades support a moderately bullish outlook.\n\n### Estimated Fair Value: $235\n\nBased on the analyst consensus average target of $212.80 and recent upgrades to $265 (Citi) and $260 (Evercore), along with the company's strategic initiatives and improving operational metrics, a fair value estimate of $235 represents reasonable upside from current levels while accounting for execution risks and market volatility.",
  "generated_date": "2026-01-24T07:22:50.260591",
  "next_refresh_date": "2026-04-25T07:22:50.260591",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.34477515000000003,
  "tokens": {
    "input": 189,
    "output": 4684,
    "cache_creation": 57357,
    "cache_read": 196198
  },
  "tldr_summary": "Charles River Laboratories International (CRL) is a leading Contract Research Organization (CRO) providing drug discovery, non-clinical development, and safety testing services globally across pharmaceutical, biotechnology, and academic research markets.\n\nKey investment highlights include a strategic focus on strengthening its scientific portfolio, implementing significant cost optimization initiatives ($295M+ in 2026), and expanding through targeted acquisitions like K.F. (Cambodia) Ltd. and PathoQuest SAS. The company maintains a strong market position in preclinical services, serving top-tier biopharma clients, with improving demand trends in its Discovery and Safety Assessment segment. Recent strategic developments include a comprehensive board review affirming its current strategic direction and disciplined capital deployment, with a new $1B stock repurchase authorization.\n\nWith an AI buy rating of 7.2/10 and an estimated fair value of $235, the stock presents moderate upside potential driven by improving operational metrics and strategic positioning in the life sciences research market."
}